Advancing the Future of GI Diagnostics

Our strong relationship with GI physicians and key opinion leaders began with the introduction of the company’s innovative diagnostic tools that have helped physicians manage the IBD patient journey. We are leveraging these relationships, our GI Biobank & advanced data mining techniques to develop breakthrough diagnostic tools that help patients and physicians from diagnosis, through disease progression, therapy selection and monitoring.

Diagnostic Pipeline

Program
Utility
IBD Population
Assay Feasibility
Development
Validation
PL-100Risk Stratification
CD
Partnered
PL-200Dosing Optimization
CD/UC
PL-300Disease Monitoring
UC
PL-400Therapy Selection
CD
PL-500Therapy Selection
CD/UC
PL-600Risk Stratification
CD
Companion DiagnosticsTreatment Stratification
CD/UC

UC: Ulcerative Colitis      CD: Crohn’s Disease

PL-100CDRisk Stratification Development
PL-200CD/UCDosing Optimization IBD Population
PL-300UCDisease Monitoring Assay Feasibility
PL-400CDTherapy Selection IBD Population
PL-500CD/UCTherapy Selection Assay Feasibility
PL-600CDRisk Stratification IBD Population
Companion DiagnosticsCD/UCTreatment Stratification Assay Feasibility